Loading…
The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy
The effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection. Patients...
Saved in:
| Published in: | Cancers 2023-05, Vol.15 (11), p.2905 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3 |
| container_end_page | |
| container_issue | 11 |
| container_start_page | 2905 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Kaibori, Masaki Yoshii, Kengo Matsui, Kosuke Matsushima, Hideyuki Kosaka, Hisashi Yamamoto, Hidekazu Nakajima, Takayoshi Aoi, Kazunori Yamaguchi, Takashi Yoshida, Katsunori Sekimoto, Mitsugu |
| description | The effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection.
Patients with HCC (
= 480) who underwent an R0 resection between 2010 and 2020 were retrospectively analyzed. Survival outcomes were investigated according to ABO blood type (A, B, O, or AB). Outcomes for type A (
= 173) and non-type A (
= 173) groups after surgery were compared using 1-to-1 propensity score matching to control for variables.
In the study cohort, 173 (36.0%), 133 (27.7%), 131 (27.3%), and 43 (9.0%) of participants had Type A, O, B, and AB, respectively. Type A and non-type A patients were successfully matched based on liver function and tumor characteristics. Recurrence-free survival (RFS; hazard ratio [HR] 0.75, 95% confidence interval [Cl] 0.58-0.98,
= 0.038) and overall survival (OS; HR: 0.67, 95% Cl: 0.48-0.95,
= 0.023) for patients with blood type A were both significantly decreased relative to non-type A patients. Cox proportional hazard analysis demonstrated that patients with HCC who have blood type A had a worse prognosis than those with non-type A blood.
ABO blood type may have a prognostic impact on patients with HCC after hepatectomy. Blood type A is an independent unfavorable prognostic factor for recurrence-free and overall survival (RFS and OS) after hepatectomy. |
| doi_str_mv | 10.3390/cancers15112905 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10251914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A752474133</galeid><sourcerecordid>A752474133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3</originalsourceid><addsrcrecordid>eNptkktP3DAUhSNUBAhYd1dZ6qabAT8SP1bVMCoPCYku6KYby2M7g1Him9oJFf--jobyEvbClv2dY5-rW1WfCT5hTOFTa6L1KZOGEKpws1MdUCzognNVf3q136-Oc77HZTBGBBd71T4TVHHJ5UH1-_bOo58JNhHyGCy66gdjRwQtWp7doLMOwKGLBNOAQkSXfjAjWN91U2cSWplkQ4TeoHPoOvgb4maLeDtC_3hU7bamy_74aT2sfp3_uF1dLq5vLq5Wy-uFraUaF0oq7wRTnGOnJGXWusZyZ5TnDbXlw446J51shFlT3LbSU1liYbvG1HO_ZofV963vMK1776yPYzKdHlLoTXrUYIJ-exPDnd7AgyaYNkSRujh8e3JI8GfyedR9yHNMEz1MWVNJ61IuLmb06zv0HqYUS76ZYkpwKfgLtTGd1yG2UB62s6leiobWoiaMFerkA6pM5_tgIfo2lPM3gtOtwCbIOfn2OSTBem4J_a4liuLL69o88_8bgP0DTdSyCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2823976876</pqid></control><display><type>article</type><title>The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Kaibori, Masaki ; Yoshii, Kengo ; Matsui, Kosuke ; Matsushima, Hideyuki ; Kosaka, Hisashi ; Yamamoto, Hidekazu ; Nakajima, Takayoshi ; Aoi, Kazunori ; Yamaguchi, Takashi ; Yoshida, Katsunori ; Sekimoto, Mitsugu</creator><creatorcontrib>Kaibori, Masaki ; Yoshii, Kengo ; Matsui, Kosuke ; Matsushima, Hideyuki ; Kosaka, Hisashi ; Yamamoto, Hidekazu ; Nakajima, Takayoshi ; Aoi, Kazunori ; Yamaguchi, Takashi ; Yoshida, Katsunori ; Sekimoto, Mitsugu</creatorcontrib><description>The effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection.
Patients with HCC (
= 480) who underwent an R0 resection between 2010 and 2020 were retrospectively analyzed. Survival outcomes were investigated according to ABO blood type (A, B, O, or AB). Outcomes for type A (
= 173) and non-type A (
= 173) groups after surgery were compared using 1-to-1 propensity score matching to control for variables.
In the study cohort, 173 (36.0%), 133 (27.7%), 131 (27.3%), and 43 (9.0%) of participants had Type A, O, B, and AB, respectively. Type A and non-type A patients were successfully matched based on liver function and tumor characteristics. Recurrence-free survival (RFS; hazard ratio [HR] 0.75, 95% confidence interval [Cl] 0.58-0.98,
= 0.038) and overall survival (OS; HR: 0.67, 95% Cl: 0.48-0.95,
= 0.023) for patients with blood type A were both significantly decreased relative to non-type A patients. Cox proportional hazard analysis demonstrated that patients with HCC who have blood type A had a worse prognosis than those with non-type A blood.
ABO blood type may have a prognostic impact on patients with HCC after hepatectomy. Blood type A is an independent unfavorable prognostic factor for recurrence-free and overall survival (RFS and OS) after hepatectomy.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15112905</identifier><identifier>PMID: 37296868</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>ABO system ; Algorithms ; Blood groups ; Comparative analysis ; Hepatectomy ; Hepatocellular carcinoma ; Hepatoma ; Liver ; Liver cancer ; Liver diseases ; Medical prognosis ; Metastasis ; Patients ; Prognosis ; Surgery ; Survival ; Survival analysis ; Tumors</subject><ispartof>Cancers, 2023-05, Vol.15 (11), p.2905</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3</citedby><cites>FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3</cites><orcidid>0000-0002-0577-3921 ; 0000-0003-0557-4321 ; 0000-0002-2926-9973 ; 0000-0003-2184-538X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2823976876/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2823976876?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37296868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaibori, Masaki</creatorcontrib><creatorcontrib>Yoshii, Kengo</creatorcontrib><creatorcontrib>Matsui, Kosuke</creatorcontrib><creatorcontrib>Matsushima, Hideyuki</creatorcontrib><creatorcontrib>Kosaka, Hisashi</creatorcontrib><creatorcontrib>Yamamoto, Hidekazu</creatorcontrib><creatorcontrib>Nakajima, Takayoshi</creatorcontrib><creatorcontrib>Aoi, Kazunori</creatorcontrib><creatorcontrib>Yamaguchi, Takashi</creatorcontrib><creatorcontrib>Yoshida, Katsunori</creatorcontrib><creatorcontrib>Sekimoto, Mitsugu</creatorcontrib><title>The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>The effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection.
Patients with HCC (
= 480) who underwent an R0 resection between 2010 and 2020 were retrospectively analyzed. Survival outcomes were investigated according to ABO blood type (A, B, O, or AB). Outcomes for type A (
= 173) and non-type A (
= 173) groups after surgery were compared using 1-to-1 propensity score matching to control for variables.
In the study cohort, 173 (36.0%), 133 (27.7%), 131 (27.3%), and 43 (9.0%) of participants had Type A, O, B, and AB, respectively. Type A and non-type A patients were successfully matched based on liver function and tumor characteristics. Recurrence-free survival (RFS; hazard ratio [HR] 0.75, 95% confidence interval [Cl] 0.58-0.98,
= 0.038) and overall survival (OS; HR: 0.67, 95% Cl: 0.48-0.95,
= 0.023) for patients with blood type A were both significantly decreased relative to non-type A patients. Cox proportional hazard analysis demonstrated that patients with HCC who have blood type A had a worse prognosis than those with non-type A blood.
ABO blood type may have a prognostic impact on patients with HCC after hepatectomy. Blood type A is an independent unfavorable prognostic factor for recurrence-free and overall survival (RFS and OS) after hepatectomy.</description><subject>ABO system</subject><subject>Algorithms</subject><subject>Blood groups</subject><subject>Comparative analysis</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkktP3DAUhSNUBAhYd1dZ6qabAT8SP1bVMCoPCYku6KYby2M7g1Him9oJFf--jobyEvbClv2dY5-rW1WfCT5hTOFTa6L1KZOGEKpws1MdUCzognNVf3q136-Oc77HZTBGBBd71T4TVHHJ5UH1-_bOo58JNhHyGCy66gdjRwQtWp7doLMOwKGLBNOAQkSXfjAjWN91U2cSWplkQ4TeoHPoOvgb4maLeDtC_3hU7bamy_74aT2sfp3_uF1dLq5vLq5Wy-uFraUaF0oq7wRTnGOnJGXWusZyZ5TnDbXlw446J51shFlT3LbSU1liYbvG1HO_ZofV963vMK1776yPYzKdHlLoTXrUYIJ-exPDnd7AgyaYNkSRujh8e3JI8GfyedR9yHNMEz1MWVNJ61IuLmb06zv0HqYUS76ZYkpwKfgLtTGd1yG2UB62s6leiobWoiaMFerkA6pM5_tgIfo2lPM3gtOtwCbIOfn2OSTBem4J_a4liuLL69o88_8bgP0DTdSyCA</recordid><startdate>20230525</startdate><enddate>20230525</enddate><creator>Kaibori, Masaki</creator><creator>Yoshii, Kengo</creator><creator>Matsui, Kosuke</creator><creator>Matsushima, Hideyuki</creator><creator>Kosaka, Hisashi</creator><creator>Yamamoto, Hidekazu</creator><creator>Nakajima, Takayoshi</creator><creator>Aoi, Kazunori</creator><creator>Yamaguchi, Takashi</creator><creator>Yoshida, Katsunori</creator><creator>Sekimoto, Mitsugu</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0577-3921</orcidid><orcidid>https://orcid.org/0000-0003-0557-4321</orcidid><orcidid>https://orcid.org/0000-0002-2926-9973</orcidid><orcidid>https://orcid.org/0000-0003-2184-538X</orcidid></search><sort><creationdate>20230525</creationdate><title>The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy</title><author>Kaibori, Masaki ; Yoshii, Kengo ; Matsui, Kosuke ; Matsushima, Hideyuki ; Kosaka, Hisashi ; Yamamoto, Hidekazu ; Nakajima, Takayoshi ; Aoi, Kazunori ; Yamaguchi, Takashi ; Yoshida, Katsunori ; Sekimoto, Mitsugu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ABO system</topic><topic>Algorithms</topic><topic>Blood groups</topic><topic>Comparative analysis</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaibori, Masaki</creatorcontrib><creatorcontrib>Yoshii, Kengo</creatorcontrib><creatorcontrib>Matsui, Kosuke</creatorcontrib><creatorcontrib>Matsushima, Hideyuki</creatorcontrib><creatorcontrib>Kosaka, Hisashi</creatorcontrib><creatorcontrib>Yamamoto, Hidekazu</creatorcontrib><creatorcontrib>Nakajima, Takayoshi</creatorcontrib><creatorcontrib>Aoi, Kazunori</creatorcontrib><creatorcontrib>Yamaguchi, Takashi</creatorcontrib><creatorcontrib>Yoshida, Katsunori</creatorcontrib><creatorcontrib>Sekimoto, Mitsugu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaibori, Masaki</au><au>Yoshii, Kengo</au><au>Matsui, Kosuke</au><au>Matsushima, Hideyuki</au><au>Kosaka, Hisashi</au><au>Yamamoto, Hidekazu</au><au>Nakajima, Takayoshi</au><au>Aoi, Kazunori</au><au>Yamaguchi, Takashi</au><au>Yoshida, Katsunori</au><au>Sekimoto, Mitsugu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-05-25</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>2905</spage><pages>2905-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection.
Patients with HCC (
= 480) who underwent an R0 resection between 2010 and 2020 were retrospectively analyzed. Survival outcomes were investigated according to ABO blood type (A, B, O, or AB). Outcomes for type A (
= 173) and non-type A (
= 173) groups after surgery were compared using 1-to-1 propensity score matching to control for variables.
In the study cohort, 173 (36.0%), 133 (27.7%), 131 (27.3%), and 43 (9.0%) of participants had Type A, O, B, and AB, respectively. Type A and non-type A patients were successfully matched based on liver function and tumor characteristics. Recurrence-free survival (RFS; hazard ratio [HR] 0.75, 95% confidence interval [Cl] 0.58-0.98,
= 0.038) and overall survival (OS; HR: 0.67, 95% Cl: 0.48-0.95,
= 0.023) for patients with blood type A were both significantly decreased relative to non-type A patients. Cox proportional hazard analysis demonstrated that patients with HCC who have blood type A had a worse prognosis than those with non-type A blood.
ABO blood type may have a prognostic impact on patients with HCC after hepatectomy. Blood type A is an independent unfavorable prognostic factor for recurrence-free and overall survival (RFS and OS) after hepatectomy.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37296868</pmid><doi>10.3390/cancers15112905</doi><orcidid>https://orcid.org/0000-0002-0577-3921</orcidid><orcidid>https://orcid.org/0000-0003-0557-4321</orcidid><orcidid>https://orcid.org/0000-0002-2926-9973</orcidid><orcidid>https://orcid.org/0000-0003-2184-538X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-05, Vol.15 (11), p.2905 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10251914 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | ABO system Algorithms Blood groups Comparative analysis Hepatectomy Hepatocellular carcinoma Hepatoma Liver Liver cancer Liver diseases Medical prognosis Metastasis Patients Prognosis Surgery Survival Survival analysis Tumors |
| title | The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T20%3A59%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Prognostic%20Impact%20of%20ABO%20Blood%20Group%20in%20Hepatocellular%20Carcinoma%20Following%20Hepatectomy&rft.jtitle=Cancers&rft.au=Kaibori,%20Masaki&rft.date=2023-05-25&rft.volume=15&rft.issue=11&rft.spage=2905&rft.pages=2905-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15112905&rft_dat=%3Cgale_pubme%3EA752474133%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c489t-989ed739660d9823ccd5c6da9e652c176d2dd8d857ab20ff8e286690cb02e6eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2823976876&rft_id=info:pmid/37296868&rft_galeid=A752474133&rfr_iscdi=true |